HeartSciences Inc. (HSCS): Nasdaq/NYSE listing notice — Heart Test receives Nasdaq delisting notice for equity non-compliance; plans appeal

HeartSciences Inc.

Received delist determination on June 20, 2023 for failing to meet $2.5M stockholders' equity by June 19 deadline.
Intends to appeal to Nasdaq Hearings Panel, which stays delisting pending hearing process.
Stock (HSCS) and warrants (HSCSW) continue trading on Nasdaq pending hearing outcome; no guarantee of extension.
Previously granted extension until June 19, 2023, but failed to comply.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HeartSciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

June 20, 2023, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension by the June 19, 2023 deadline. The Company intends to timely appeal the Staff's delisting determination by submitting a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request will automatically stay the delisting of the Company's securities by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to

View on SEC.gov

Browse all listing & compliance notices →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.